B
BioLine RX Ltd
TASE:BLRX
BioLine RX Ltd
TASE:BLRX
Price:
1.5
ILS
7.14%
Market Closed
Market Cap:
₪34.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioLine RX Ltd
Cash from Investing Activities
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
BioLine RX Ltd
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Cash from Investing Activities
-$8.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Investing Activities
-$9.8m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash from Investing Activities
-$1.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Investing Activities
$61.6m
|
CAGR 3-Years
287%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Investing Activities
-$107k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash from Investing Activities
$5.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
BioLine RX Ltd
Glance View
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BLRX
Intrinsic Value
0.36
ILS
Overvaluation 76%
B
See Also
What is BioLine RX Ltd's Cash from Investing Activities?
Cash from Investing Activities
-8.5m
USD
-8.5m
USD
Based on the financial report for Dec 31, 2025, BioLine RX Ltd's Cash from Investing Activities amounts to -8.5m USD.
What is BioLine RX Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
6%
6%
